Development of predictive computational models for cancer patient outcomes based on molecular and clinical data. This service enables personalized prognosis and treatment planning.
Manufactured by
PreceDo Pharmaceuticals Co.Ltd.
China
PreceDo Pharmaceuticals is a state-controlled high-tech enterprise established in 2015, affiliated with Chinese Academy of Sciences Hefei Institute. The company specializes in cell engineering technology, featuring proprietary HDS tumor precision medication technology, Ba/F3 cancer kinase target engineered cell library, and an approved renewable cancer primary cell biobank for anti-tumor drug development and clinical precision treatment.
© 2026 Suplivia · Home · Browse Products